Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue)

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

June 27, 2022

Study Completion Date

June 27, 2022

Conditions
Systemic Sclerosis
Interventions
DRUG

"ACHIM as solute (10^9 intestinal microbes/ml)"

Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.

Trial Locations (4)

Unknown

Haukeland University Hospital, Bergen

Oslo University Hospital, Oslo

University hospital of North Norway, Tromsø

St. Olavs hospital, Trondheim university hospital, Trondheim

All Listed Sponsors
collaborator

South-Eastern Norway Regional Health Authority

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

St. Olavs Hospital

OTHER

collaborator

University Hospital of North Norway

OTHER

lead

Oslo University Hospital

OTHER

NCT04300426 - Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue) | Biotech Hunter | Biotech Hunter